Mark Vincent
Direktor/Vorstandsmitglied bei APTOSE BIOSCIENCES INC.
Vermögen: 422 $ am 31.05.2024
Profil
Mark D.
Vincent is the founder of Sarissa, Inc. (founded in 2000) where he holds the title of Chief Executive Officer & Director since 2011.
He is currently working as an Independent Director at Aptose Biosciences, Inc. since 2007 and as an Associate Professor at the University of Western Ontario since 2008.
Dr. Vincent has previously worked as a Director at DRI Capital, Inc. and as a Director-Investigational Oncology at YM BioSciences, Inc. He obtained his doctorate degree from the University of Cape Town in 1976.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
APTOSE BIOSCIENCES INC.
0,00% | 29.04.2024 | 433 ( 0,00% ) | 422 $ | 31.05.2024 |
Aktive Positionen von Mark Vincent
| Unternehmen | Position | Beginn |
|---|---|---|
| APTOSE BIOSCIENCES INC. | Direktor/Vorstandsmitglied | 19.09.2007 |
| Sarissa, Inc. | Gründer | 01.01.2000 |
| University of Western Ontario | Corporate Officer/Principal | 01.01.2008 |
Ehemalige bekannte Positionen von Mark Vincent
| Unternehmen | Position | Ende |
|---|---|---|
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Direktor/Vorstandsmitglied | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Ausbildung von Mark Vincent
| University of Cape Town | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Sarissa, Inc. | |
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
